Anthrax vaccine maker Emergent sets IPO terms
Reuters
WASHINGTON, Oct 24 (Reuters) - Anthrax vaccine maker Emergent Biosolutions Inc. filed with the U.S. Securities and Exchange Commission on Tuesday to sell up to 5 million shares for between $14 and $16 apiece in an initial public offering.
Underwriters, led by JPMorgan, have the option to buy an additional 750,000
shares to cover over-allotments, according to the filing with the SEC.
The Gaithersburg, Maryland-based company has applied for a Nasdaq listing under the symbol "EBSI" (EBSI.O: Quote, Profile, Research).
WASHINGTON, Oct 24 (Reuters) - Anthrax vaccine maker Emergent Biosolutions Inc. filed with the U.S. Securities and Exchange Commission on Tuesday to sell up to 5 million shares for between $14 and $16 apiece in an initial public offering.
Underwriters, led by JPMorgan, have the option to buy an additional 750,000
shares to cover over-allotments, according to the filing with the SEC.
The Gaithersburg, Maryland-based company has applied for a Nasdaq listing under the symbol "EBSI" (EBSI.O: Quote, Profile, Research).
